Hints and tips:
...Ian hit Florida’s west coast on September 28 near the town of Fort Myers as a Category 4 storm, crossed the state to the Atlantic and then went on to hit South Carolina on September 30....
...“Some of the individuals who worked for the president [ . . .] distinguished themselves,” said Julie Myers Wood, who worked on the independent counsel’s investigation into Bill Clinton....
...Dr Julie Vose, president of Asco, describes the results as “very positive” and says physicians would have typically expected just 5 per cent of such patients to have survived for at least three years before...
...According to Asco’s president, Dr Julie Vose, it has now given itself a remit to consider whether new medicines are good value....
...“The rise in condo development shows how much confidence developers have in the Charlotte market,” says Julie McGee Sharpe of estate agency Redfin....
...Bristol-Myers Squibb’s effort last year to buy ImClone, its longstanding partner, failed after ImClone said it deserved a higher bid and eventually secured one from Eli Lilly....
...Sanofi-Aventis of France, which recently appointed a new chief executive, is among rivals likely to launch takeovers, while long-cited targets in the industry include Biogen Idec, Bristol-Myers Squibb and...
...Sanofi-Aventis, of France, which appointed a new chief executive, is among rivals likely to launch takeovers, while long-cited targets include Biogen Idec, Bristol-Myers Squibb and Amgen....
...Shares of ImClone traded 5.2 per cent higher at $62.50, as investors bet that Bristol-Myers’ latest foray would not represent the highest bid for the company, either from Bristol-Myers or another suitor....
...Amgen, Bristol-Myers Squibb and Schering Plough have all been cited as potential targets, while Roche Holding, the world’s biggest maker of cancer medicines, was still trying to put together the financing...
...Bristol-Myers’ $62 per-share bid values the remainder of the company that it does not own at $4.7bn....
...But Bristol-Myers refused on Thursday to raise its $60 per share bid, which would give it control of the 83 per cent of ImClone it does not already own....
...Bristol-Myers pays ImClone 39 per cent of its North American net sales of Erbitux. A merger would give Bristol-Myers full access to the Erbitux revenue stream....
...Additional reporting by Julie MacIntosh in New York...
...Bristol-Myers and ImClone have been partners in making Erbitux since 2001, and Bristol-Myers is ImClone’s largest shareholder....
...Pressure was mounting on Bristol-Myers Squibb on Thursday to raise its $62 a share unsolicited offer for ImClone, the US biotech company, which said it was continuing negotiations with a second “mystery...
...Roche’s about-face, combined with Bristol-Myers’ bid for the rest of its partner ImClone, is now sparking debate over whether other drugmakers that partner with smaller companies on key ventures will enact...
...The $4.1bn buy-out of Bristol Myers’ ConvaTec business, however, ranked as the largest private equity deal announced in the first half of this year – a far cry from the $39bn buy-out of Equity Office Properties...
...Citigroup and Morgan Stanley advised Bristol-Myers....
...Roll up for a Mike Myers comedy in which the Austin Powers star dons wig and twirly beard. He plays a California maharishi administering wisdom to Jessica Alba, Justin Timberlake and others....
...Mr Bush also named Julie Myers as assistant secretary of homeland security for immigration and customs enforcement, despite earlier criticism that she did not have sufficient experience with immigration...
...Yet the nominee for its enforcement, the 30-something Julie Myers, seems better- known for her connections (Bush White House, niece of America’s top soldier, just married a cabinet secretary’s right- hand...
International Edition